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OVERVIEW
Genomic studies have shown that large numbers of candidate targets are observed in breast cancer. Nevertheless, only a few of them
are validated as relevant targets in clinical studies. Estrogen receptor (ER) and HER2 expressions could be associated with a level I
evidence. Beyond ER and HER2, BRCA and PIK3CA mutations (when targeted with alpha-speciﬁc PI3K inhibitors) could be considered
as promising targets in breast cancer since they have been associated with objective responses in phase I/II trials. In addition to these
four molecular alterations, several others have shown promising results in preclinical studies and are being investigated in clinical trials.
These genomic alterations include AKT1, ERBB2, and ESR1 mutations. These considerations highlight the lack of evidence for using
multiplex technologies to individualize therapy in metastatic breast cancer. Sequencing multiple genes to treat metastatic breast
cancer is very promising but should be done in the context of clinical trials, either to enrich phase I/II trials in patients with genomic
alterations or to show medical usefulness of new biotechnologies like next-generation sequencing (NGS). Although most current
approaches of precision medicine are aiming at targeting drivers, additional applications could be developed in the future. This includes
the identiﬁcation of DNA repair deﬁciencies, mechanisms of immune suppression, and identiﬁcation of minority lethal subclones. Finally,
one of the very promising applications of genomics for metastatic breast cancer is the identiﬁcation of pathway activation or defects
at the individual level. For example, gene expression and single nucleotide polymorphisms (SNP) signatures are being developed to
detect kinase (such as mammalian target of rapamycin [mTOR]/CDK4) activations or DNA repair deﬁciencies.
Molecular studies have shown that breast cancer in-cludes a large number of subgroups defıned by the
presence of a specifıc genomic or protein alteration. ER ex-
pression was the fırst validated target in breast cancer, lead-
ing to the optimal development of endocrine therapy.1 In the
late 1990s,HER2overexpressionwas validated as a target and
was shown to be a predictive biomarker for the effıcacy of
trastuzumab.2 During the 2000s, genomic analyses based on
gene expression arrays suggested that breast cancer could be
divided into four different subgroups: luminal A, luminal B,
HER2-enriched, and basal-like.3-5 Further studies have sug-
gested that basal-like cancers can be subdivided into six sub-
groups.6 More recently, studies on NGS have suggested that
approximately 40 genomic alterations can be found in pri-
mary breast cancers.7,8 Overall, this introduction emphasizes
that each single breast cancer presents a specifıc molecular
profıle and specifıcmolecularmechanisms of cancer progres-
sion. Parallel to the advances in the understanding of disease
biology, several advances in technology could dramatically
change patient care. Indeed, it has been shown that high-
throughput DNA sequencing together with comparative
genomic hybridization (CGH; copy number analyses) can be
performed robustly in the clinical practice.9,10 This has led to
the development of precision medicine that involves multi-
plexmolecular analyses to identifymolecularmechanisms of
cancer progression in each individual in order to improve
treatment. In the following review, we present the current
state of this approach in metastatic breast cancers (mBC).
Several technologies are available to identify genomic altera-
tions in individuals. First, sequencing allows for the detection
of mutations. Sanger sequencing, the original method of se-
quencing, is an approach that allows analysis of only a few
genes at the same time. NGS allows sequencing large number
of DNA bases in a single run. This latter technology allows
multigene sequencing for precision medicine purposes. In
some specifıc platforms and conditions, NGS can also allow
quantifying gene copy numbers, although CGH array or flu-
orescence in situ hybridization analyses are usually better for
this purpose. Finally, gene expression array and reverse tran-
scription polymerase chain reaction quantify gene expres-
sion. More recently, RNA sequencing is being developed to
assess gene expression, translocations, and mutations.
LEVEL OF EVIDENCE SCALE FOR DRUG TARGETS
NGS and other high-throughput technologies analyze sev-
eral hundred or thousands of genes in the same assay. These
technologies can identify many genomic alterations in each
patient. Nevertheless, only a few of them are truly implicated
in the disease progression. A level of evidence scale that ranks
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targets according to their relevance has been developed to
facilitate interpretation of these high-throughput assays, bet-
ter communicate results to patients, and prioritize research
needs.11 Level I evidence includes molecular alterations that
have been shown to be validated targets, either based on
phase III trials or several large phase I/II trials. Level II evi-
dence includes molecular alterations associated with re-
sponse to treatment in small or unique phase I/II trials. Level
IIImolecular alterations include those that have been consid-
ered as promising targets based on preclinical studies. Fi-
nally, level IV evidence includes genomic alterations that are
selected based on bioinformatics analyses only, without bio-
logic studies to support them. This level of evidence scale also
makes a difference according to whether the molecular alter-
ation has been investigated in the same disease and whether
studies included negative controls (evidence that patients
without the alteration do not derive benefıt from the targeted
therapies). This level of evidence scale does not evaluate the
medical usefulness of targeting the molecular alteration
(benefıt as compared with standard of care), but the antitu-
mor activity obtained by targeting it. In the next sections of
this article, we will use this level of evidence scale to classify
molecular alterations in breast cancer. From this analysis, we
will further discuss the current positioning ofmultiplex assay
to treat patients with breast cancer.
MOLECULAR TARGETS AND THEIR RESPECTIVE
LEVEL OF EVIDENCE IN BREAST CANCERS
Molecular alterations can be divided between drivers, mech-
anisms of resistance,mutational process andDNA-repair de-
fects, immune alterations, cell death, angiogenesis, and
metabolism. These latter three systems will not be discussed
in the present article. The list of themost investigatedmolec-
ular alterations and their level of evidence are reported in
Table 1.
Oncogenic drivers can be defıned as molecular alterations
involved in malignant transformation and cancer progres-
sion. Targeting a driver is expected to lead to tumor shrink-
age (known as oncogene deaddiction). As mentioned in the
introduction, the two historic drivers include ER expression
and ERBB2-amplifıcation. These two targets are associated
with level I evidence. Additional candidate molecular altera-
tions are being investigated in breast cancer. These altera-
tions should be divided between DNA-based assays and
pathway-based assays. At the DNA level, there are between
10 to 20 genomic alterations that are currently the targets of
drug development.
PIK3CA mutations are observed in approximately 25% of
breast cancers, mainly those with ER or HER2 expression.12
PI3K activates AKT1 that subsequently activates mTOR.
AKT1 also interact with pathways that do not relate with
mTOR, including FOXO,BAD, andGSK3. Several drug fam-
ilies target PI3K/AKT/mTOR pathways, including mTOR
inhibitors, AKT inhibitors, nonselective PI3K inhibitors, and
alpha-selective PI3K inhibitors. In an ancillary study of the
BOLERO2 trial, PIK3CA mutations were not predictive for
the effıcacy of mTOR separate inhibitors in ER-positive/
HER2-negative breast cancer.13Nonselective PI3K inhibitors
target most of the PI3K subunits and thus present a narrow
therapeutic index. These drugs can therefore achieve modest
PI3K inhibition. This could explain why nonselective PI3K
inhibitors have shown mitigated results in phase II random-
ized trials.14 Conversely, alpha-selective inhibitors are very
potent inhibitors of alpha subunit, a major player of PI3K
activity in cancer. Interestingly, phase I studies using alpha-
selective PI3K inhibitors have shown extremely encouraging
results in patients who with PIK3CA mutations, suggesting
that PIK3CAmutation could be a relevant target inmBC.15,16
This genomic alteration should be ranked level IIa. Activat-
ingAKT1mutation is the other genomic alteration located in
KEY POINTS
 Only a few molecular alterations are validated as targets in
breast cancer (speciﬁcally ER and HER2 expression).
 Driver identiﬁcation in breast cancers includes DNA-based
analyses but also detection of pathway activation and
dependency (e.g., ER, mTOR, and CDK4).
 Driver identiﬁcation is not the sole application of genomics
to personalize therapy for metastatic breast cancer.
 There is no evidence that using multiplex genomic testing
for metastatic breast cancer improves outcomes.
 Ongoing trials are evaluating the medical usefulness of next-
generation sequencing in metastatic breast cancers.
















































Abbreviations: ER, estrogen receptor; mTOR, mammalian target of rapamycin; ND, not
determined; PD-L1, programmed death ligand 1.
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the pathway. First, AKT1mutations occur in approximately
3% of breast cancers. These alterations are oncogenic in
preclinical models and have been associated with objective
response to mTOR inhibitors in molecular screening pro-
grams.10 Ongoing studies are investigating the effıcacy of
AKT inhibitors in patients with this genomic alteration. Al-
though some retrospective analyses suggest oncogene dead-
diction in patients with AKT1 mutations, this target is still
considered to be a level III target.
FGFR1 amplifıcations occur in approximately 10% of
breast cancers, mainly those with ER expression. This alter-
ation has been associated with very promising results in pre-
clinical studies.17Nevertheless, treatmentwith highly specifıc
and bioactive FGFR inhibitors failed to demonstrate antitu-
mor activity in phase I trials.18 Interestingly, multikinase in-
hibitors like lucitanib were associated with promising
antitumor activity in patients presenting FGFR1 amplifıca-
tions,19 but whether this antitumor activity relates to FGFR
inhibition is unclear. FGFR1 amplifıcation could be associ-
ated with level III evidence as a target.CCND1 is amplifıed in
approximately 15% of breast cancers. This amplifıcation is
not clearly associated with CCND1 expression, and clinical
studies have failed to validate that CCND1 amplifıcation are
relevant targets in breast cancer.20 Finally, the last interesting
target located on tyrosine kinase is ERBB2mutations. These
mutations have been shown to be activatingmutations and to
be associated with antitumor activity of neratinib, a HER2
inhibitor.21 Phase II trials are ongoing. This target is cur-
rently considered as level III evidence but could jump to level
I if consistent studies report high levels of antitumor activity
for neratinib in this genomic segment.
Besides alterations at theDNA levels, assessing pathway ac-
tivation and dependency could provide relevant information
about driving forces of cancer progression. To illustrate, ER
expression drives cancer progression in ER-positive breast
cancer, although no alteration is usually detected at the DNA
level. This emphasizes the relevance of assessing pathway ac-
tivation in breast cancer. The Cancer Genome Atlas data
have suggested that PI3K/AKT/mTOR and CDK4/Rb path-
ways are the two most relevant targetable pathways in breast
cancer. Gene expression signatures could provide informa-
tion about activation status of these pathways, together with
assessment of phosphoproteins. For example, in the BO-
LERO3 trial, biomarker studies showed that activation of
mTOR (specifıcally PS6K) is associated with high sensitivity
to everolimus.
Emergence of lethal subclone is a well-described mechanism
of resistance to targeted therapies. In patients with lung cancer,
it has been well documented that T790M mutations, although
theminority at the timeofdiagnosis, becomepredominant after
resistance to EGFR inhibitors.22 In breast cancer, a similar phe-
nomenon is being observed with ESR1. ESR1 is the gene that
encodes for ER. Although less than 1% of early breast cancers
present mutations, it is considered that between 10% to 30% of
breast cancers resistant to aromatase inhibitors will have a hot-
spot mutation thus leading to ligand-independent activation of
the receptor.23,24 It has been suggested from preclinical works
that high-dose fulvestrant could present some antitumor activ-
ity in this subset of patients. Several new ER degraders like
GDC-0810 are being developed in this setting (NCT01823835).
Until now, this target is classifıed level III. There are several
questions surrounding this genomic alteration that could have
some clinical influence. First, as opposed to T790M, this muta-
tion has not yet been reported in a minority subclone in a pri-
mary tumor. Finding theESR1mutation inaminority clone ina
primary tumor would open the path for the development of
ultra-deep sequencing to detect them and potentially treating
them very early during the disease course. Second, the use of
circulating DNA could help detect these mutations during the
disease course and treat them early. Finally, one study has sug-
gested that ESR1mutations could be associated with very poor
outcome. If validated, this fınding would suggest that this
genomic segment would deserve some fast-track approvals
based on phase II data.
The third application for genomic tests is the identifıcation of
DNA repair defects and mutational processes at the individual
level. Identifying DNA repair defects could lead to administra-
tion of personalized synthetic lethality strategies or specifıc
genotoxic agents. The best example in breast cancer is provided
by BRCA1 and BRCA2mutations. When biallelic, BRCA1 and
BRCA2mutations and/or loss lead to homologous recombina-
tion defıciency and genomic instability. BRCA1/2 mutations
have been associated with sensitivity to PARP1 inhibitors (syn-
thetic lethality) andDNAalkylating agents (genotoxic).25 Inter-
estingly in these trials, patientswithoutBRCA1/2 alterations did
not present a similar degree of antitumor activity as compared
with patients with mutations. Based on these consistent data
fromphase III and largephase IIprograms,BRCA1/2mutations
as drug targets have a level I evidence.11 The controversy in this
area is more about how to position each therapeutic strategy
(PARP1 inhibition and DNA alkylating agents) and to show
medical usefulness over standard of care, rather than whether
BRCA1/2mutations constitute a target per se. The second con-
troversy is about whether some functional tests evaluating ho-
mologous recombination defıciency (HRD) could have better
performance than detecting BRCA1/2 mutations. HRD tests
could have better performance either by selecting the right pa-
tientwith theBRCA1/2mutationor by identifyingpatientswith
BRCA1/2wild-typewhopresentwithHRD.Whenassessed ret-
rospectively, theHRD test developed byMyriadwas not associ-
ated with a differential sensitivity between platinum and
docetaxel. The HRD test developed by Clovis has been associ-
atedwithsensitivity to thePARPinhibitor rucaparib, even in the
absence ofBRCAmutation.26Anongoingphase II trial (RUBY)
is testing whether rucaparib could present antitumor activity in
patients with BRCA1/2wild-typewho present a highHRD. Be-
yond HRD and BRCA, assessing other DNA repair genes or
pathways couldallowexpanding thearrayofpatientswhocould
be eligible for synthetic lethality strategies. ATM and ATRmu-
tations are observed in approximately 2% of breast cancers and
could defıne a subset of patients eligible for synthetic lethality
approaches. In terms of pathways, several studies have sug-
gested that themutational pattern detected bywhole-exome se-
quencingcouldallow fordefıningwhichDNArepairpathway is
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altered ineach individual.27Thiscouldpotentially lead to theuse
of whole-exome sequencing to individualize synthetic lethality
approaches for patient treatment.
Finally, the fourth potential application fıeld of genomics
to individualize therapy is immunology. Genomics could al-
low detecting neoantigens and expression of ligands for im-
mune checkpoints,28 but also test the competence of the
cancer cell to present antigens and to be killed. Recent data
obtained in metastatic triple-negative breast cancer suggest
that anti-PD-1 antibody could present some antitumor activ-
ity.29 Finally, genomic tests could evaluate whether the host
could generate an antitumor immune response following im-
munogenic cell death.30 For example, TLR4 polymorphisms
confer lack of immunogenicity andhave been associatedwith
resistance to anthracyclines in patients with breast cancer.30
CLINICAL DEVELOPMENT OF PRECISION MEDICINE
IN METASTATIC BREAST CANCER: WHICH
TECHNOLOGY? WHICH SAMPLES? WHICH TRIALS?
As discussed in the previous section, there are large numbers
of applications for genomics to better treat patients in the
metastatic setting. Each application deserves a specifıc tech-
nology and it is important to defıne which technology will be
developed for which purpose. Current approaches of preci-
sion medicine aims at identifying drivers at the DNA level.
For this purpose, sequencing is the best technology.Whether
sequencing should be based on Sanger technology or should
consist in NGS depends on the number of genes to be tested.
An important aspect of breast cancer is the high number of
copy number alterations that could potentially drive cancer
progression. Assessing gene copy numbers requires fluores-
cence in situ hybridization technology for a single or a few
genes, or CGH/SNP arrays for a large number of genes. In-
terestingly, some centers can now robustly assess copy num-
ber using NGS technology.9 This therefore makes this
technology a preferred choice for clinical research programs
that aim to identify drivers inmBC. Alternatively, circulating
DNA could be useful when biopsies are not feasible. Asmen-
tioned previously, assessment of pathways activation could
be done by gene expression arrays, reverse transcription
polymerase chain reaction, or phosphoprotein assays. Other
technologies could be dedicated to specifıc purposes of clin-
ical research. First, ultra-deep sequencing could be an inter-
esting approach to detect minority clones, and circulating
DNA could be an interesting approach to detect the appear-
ance of resistance. SNP array could be interesting to quantify
HRD. On a long-term perspective, one could argue that the
best approach to personalize therapy will be to apply whole-
exome sequencing to hard-to-treat mBC. Whole-exome se-
quencing offers the advantage of detecting both drivers,
DNA repair defects and neoantigens.28 Finally, RNA se-
quencing could offer the advantage of detecting pathway ac-
tivation and target expression.
One fıeld for controversy is which sample should be used for
target identifıcation in patients. Primary tumors offer the ad-
vantage of being accessible and not requiring additional biop-
sies.Nevertheless, several studies have shown that targets canbe
lost or gained during the disease evolution.31More recently, ev-
idence has been reported that targets acquired during the dis-
ease course—although not trunk alterations—could drive
cancer progression.32 This emphasizes the need to assess
genomic andmolecular targets at the timeof treatment decision
and start. Assessing cancer biology at the time of treatment de-
cision would need to perform biopsies of metastatic sites.
Whenever this is feasible, biopsyofmetastatic sites shouldbe the
priority since it allows assessing genomic alterations but also
RNA and protein expression together with immune markers.
Nevertheless, if the tumor site is diffıcult to biopsy or in case of
bone disease, circulating DNA could be a possible alternative.
Until now, there has been no data to support the use of
DNA- or RNA-based technologies in daily practice for pa-
tients with mBC. Several nonrandomized trials have been
performed but they did not provide a clear picture about the
potential medical usefulness of precisionmedicine for breast
cancer. In the SAFIR01 trial,10 approximately 28% of the pa-
tients presented evidence of antitumor activity but only 10%
had an objective response. These numbers align with phase
I/II trials that tested drugs without molecular selection. In a
clinical trial testing gene expression, Von Hoff et al reported
that a group of patients had their progressive-free survival
prolonged under genomic-based therapy.33 Nevertheless,
this trial did not have a control group with patients treated
with the same treatments but not driven by genomics. Out-
side of these two trials, there is no large study reporting effı-
cacy of genomics in mBC, and therefore, with the exception
of prospective clinical trials, multiplex approaches cannot be
recommended for routine practice.
The next question is how to provide evidence that the use of
genomics improves outcomes in patients with mBC. There are
twopossible strategies to address this question.The fırst strategy
consists of prospectively validating each target in large clinical
trials. This strategy is currently beingused inmost of the clinical
programs in breast cancer. For example, HER2 inhibitors are
beingdeveloped inpatientswithERBB2mutations, PI3K inhib-
itors are being developed in patients with PIK3CA mutations,
AKT inhibitors in patients with AKT1 mutations, and so on.
This approach will lead to the clinical validation of several
genomic alterations. Once the number of such genomic altera-
tions is large enough, companion diagnosis will very likely
switch from Sanger single-gene sequencing to NGS. The sec-
ond approach will consist of the clinical validation of a
multiplex approach. In this design, the trial does not aim to
validate each genomic alteration, but to test the hypothesis
that using a multiplex technology improves outcomes. For
example, the SAFIR02 trial (NCT02299999) is testing the hy-
pothesis that use of NGS and CGH arrays improves out-
comes compared with standard of care.
MOVING TO RATIONALE COMBINATIONS
As previously mentioned, breast cancer is a complex disease in
which each patient could present several altered genomic alter-
ations and pathways. Therefore, there is a strong rationale to
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combinedrugs in the eraofmolecularmedicine.There are three
possibleways of combiningdrugs. First, drugs canbe combined
based on the presence of multiple genomic alterations. It has
been suggested that multiple genomic alterations on drivers
could be associated with resistance to therapy.34 Combining
drugs that target different genomic alterations could therefore
lead to antitumor activity. This is the rationale to combine
HER2 and PI3K inhibitors in patients with ERBB2-amplifıed,
PIK3CA-mutated BC. The second rationale to combine thera-
pieswould be to targetmolecular processes in different systems.
Forexample,ERBB2-amplifıedBCisassociatedwithahigh level
of PD-L1 expression andPD-L1-induced immune suppression.
There is therefore a rationale to combine HER2-inhibitors and
anti-PD-1 in patients presenting ERBB2-amplifıed and PD-L1-
induced immunesuppression(PANACEA;NCT02129556).Fi-
nally, other combinations will aim at avoiding cancer cell
adaptation. For example, cancer cells presenting aPIK3CAmu-
tation can further adapt to PI3K inhibitors through CDK4 or
mTOR activation. This provided a rationale to evaluate triple
combinations therapy.
CONCLUSIONS AND PERSPECTIVES
A high number of gene or molecular alterations could be con-
sideredasactionable inbreast cancer.Nevertheless, onlya fewof
them (ER, HER2 expressions, and—to a lesser extent—BRCA
and PIK3CAmutations) are currently validated as relevant tar-
gets.There is thereforenorobust evidence thatusingamultiplex
technology in mBC improves patient outcomes. Nevertheless,
this approach could allow for accelerated drug development by
detecting patientswith genomic alterations anddriving them to
phase I/II trials. The current approach to validating genomics
for mBC consists of testing drug effıcacy in each genomic seg-
ment by validating each molecular alteration one by one. Since
most of these genomic alterations are rare, there is a need to de-
velop very largemolecular screeningprograms. Several interna-
tional screening programs have been set up recently including
the AURORA program, developed by Breast International
Group. Alternative development of precision medicine could
consist of evaluating the overall effect of sequencing technolo-
gies in the whole population of patients with breast cancer, in-
dependently of each single alteration. This approach is being
used in the SAFIR02 trial. Finally, oneof themajor challenges in
the future will be optimally to implement these new technolo-
gies to secure access to innovations for all patients. To achieve
this goal, the Institut National du Cancer has set up 28 public
genomic centers in France that have a goal to offer access to
genomic tests for free to all patients with cancer. This model,
initially based on Sanger sequencing, is currently moving to
NGS.
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